Edgewise Therapeutics, Inc.
EWTX
Ранг среди акций
#3979
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Цена акции
$38.12
Последняя синхронизация: 2026-10-19
Рыночная капитализация
$4.10B
Изменение (1 день)
2.50%
Изменение (1 год)
147.69%
Страна
US
Торговля Edgewise Therapeutics, Inc. (EWTX)
Категория
Healthcare
Коэффициент P/S для Edgewise Therapeutics, Inc. (EWTX)
Коэффициент P/S на October 2026 TTM: 0.00
Согласно последним финансовым отчетам и цене акций Edgewise Therapeutics, Inc., текущий коэффициент P/S (TTM) составляет 0.00. В конце 2023 он составлял 0.00.
История P/S для Edgewise Therapeutics, Inc. с 2019 по 2026
Коэффициент P/S в конце каждого года
| Год | P/S | Изменить |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
Коэффициент P/S для аналогичных компаний или конкурентов
| Компания | P/S | Разница P/S | Страна |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
